tbuckley/cabot-search huggingface dataset:
Abstract 12114: Safety and Efficacy of Sitagliptin plus Granulocyte-colony Stimulating Factor in Patients Suffering From Acute Myocardial Infarction (Sitagrami Trial) - Primary and Secondary Analyses
Authors: Christoph Brenner, Hans D Theiss, Christine Adrion, Ulrich Grabmaier, Daniel Theisen, Franz von Ziegler, Alexander Leber, Alexander Becker, Hae-Young Sohn, Ellen Hoffmann, Ulrich Mansmann, Gerhard Steinbeck, Wolfgang-Michael Franz
Journal: Circulation (2015)

Introduction: In animal models, we have previously shown that a combined progenitor cell therapy comprising G-CSF treatment and a pharmacological inhibition of DPP4 can enhance the recruitment of circulating progenitor cells (ciPCs) into the ischemic cardiac tissue via the SDF1/CXCR4 signaling. Within the myocardium, these bone marrow-derived cells can mediate local regenerative effects. Mainly via a paracarine action ciPCs thus reduce adverse cardiac remodeling, inhibit apoptosis and enhance heart function and survival. Due to these promising preclinical results, we transferred our therapeutic concept into the phase III, multi-center, randomized, double blind and placebo-controlled SITAGRAMI trial. The purpose of the study was to assess the therapeutic impact of a combined pharmacological progenitor cell therapy using G-CSF and the DPP4 inhibitor Sitagliptin (G+S) after severe acute myocardial infarction (EudraCT Number: 2007-003941-34; www.clinicaltrials.gov; registration number: NCT00650143). Methods and Results: The enrolled 174 patients suffered from large myocardial infarction and underwent successful percutaneous coronary intervention within 24 hours after initiation of symptoms. We randomized patients in a 1:1 ratio to a treatment with either placebo or a combination of G-CSF for 5 days and Sitagliptin for 4 weeks. We executed Cardiac MRI in all patients at screening visit and after 6 months and planned additional clinical follow-up visits 6 and 52 weeks after the index event. In our final analysis, placebo treated patients showed a mean change in left ventricular EF after 6 months of 4.6%. This exactly corresponds to the changes reported 6 months after acute myocardial infarction by previously published clinical trials. Conclusions: Besides the primary endpoint data (change of left and right ventricular ejection fraction (EF) from screening to 6 months of follow-up) and general safety analyses, we will report about various secondary endpoints including cardiac volumes and myocardial perfusion. Furthermore, we will present additional analyses on the occurrence of major adverse cardiac events, in stent restenosis as well as de novo stenosis, gender specific-differences and various subgroup analyses.
Abstract P277: Orthostatic Hypotension Predicts Arterial Stiffness Later in Life
Authors: Georgina Crichton, Merrill Elias
Journal: Circulation (2017)

Arterial stiffness is a major risk factor for myocardial infarction, stroke, end-stage renal disease and other cardiovascular diseases. It is now recognized that measures of central arterial function are better and more useful predictors of vascular health outcomes than measures of traditional blood pressure, and pulse wave velocity (PWV) is now considered the gold standard non-invasive method for measuring aortic stiffness. The aim of the present study was to test the hypothesis that orthostatic changes (hypo- or hypertension) may be related to arterial stiffness, as inferred by PWV over a five year period, with consideration given to other cardiovascular risk factors, lifestyle and PWV-related variables. Orthostatic hypotension was defined as a fall in systolic blood pressure of 20 mm Hg or more, or in diastolic blood pressure of 10 mm Hg or more, and orthostatic hypertension as a rise in systolic blood pressure or 20 mm Hg or more. The majorprospective analysis was undertaken on 503 community-dwelling participants (mean age 61 years, 60% women) from the Maine-Syracuse Longitudinal Study (MSLS). At baseline, the prevalence of orthostatic hypotension and hypertension was 3.9% and 4.9%, respectively. Orthostatic blood pressure variables were related to PWV, after adjustment for demographic, cardiovascular, lifestyle and PWV-related factors. Arterial stiffness was significantly greater in those with orthostatic hypotension (12.1 ± 0.56 m/s) than in those without (10.5± 0.11 m/s), measured up to five years later, with full multivariate adjustment. Orthostatic hypertension was not associated with arterial stiffness. In conclusion, we found that orthostatic hypotension predicts arterial stiffness later in life.
Abstract 542: Angiotensin II-Induced Leptin Secretion in Rat Neonatal Cardiomyocytes is Mediated by Two Different Mechanisms Involving JAk-STAT and NF-kB Activation
Authors: Venkatesh Rajapurohitam, Sabzali Javadov, Daniel Purdham, Morris Karmazyn
Journal: Circulation (2006)

Introduction: Leptin is a 16 kDa protein produced primarily by adipose tissue but recently we demonstrated that it is also synthesized in heart and cardiomyocytes. In addition, we identified leptin...
A Neuroethics Backbone for the Evolving Canadian Brain Research Strategy
Authors: Judy Illes, Samuel Weiss, Jaideep Bains, Jennifer A. Chandler, Patricia Conrod, Yves De Koninck, Lesley K. Fellows, Deanna Groetzinger, Eric Racine, Julie M. Robillard, Marla B. Sokolowski
Journal: Neuron (2019)
Activating mutations in PIK3CD disrupt the differentiation and function of human and murine CD4+ T cells
Authors: Julia Bier, Geetha Rao, Kathryn Payne, Henry Brigden, Elise French, Simon J. Pelham, Anthony Lau, Helen Lenthall, Emily S.J. Edwards, Joanne M. Smart, Theresa S. Cole, Sharon Choo, Avni Y. Joshi, Roshini S. Abraham, Michael O'Sullivan, Kaan Boztug, Isabelle Meyts, Paul E. Gray, Lucinda J. Berglund, Peter Hsu, Melanie Wong, Steven M. Holland, Luigi D. Notarangelo, Gulbu Uzel, Cindy S. Ma, Robert Brink, Stuart G. Tangye, Elissa K. Deenick
Journal: Journal of Allergy and Clinical Immunology (2019)
Academic Advancement in the Current Era
Authors: Keri M. Shafer, Ravi S. Hira, Shashank S. Sinha, Michael Pfeiffer, Islam Abudayyeh, Dmitriy N. Feldman, Steve Leung, Julie Damp, Rakesh Gopinathannair, Anne Marie Valente, Chittur A. Sivaram, Andrew M. Freeman
Journal: Journal of the American College of Cardiology (2019)
Eicosanoid mediator profiles in different phenotypes of nonsteroidal anti‐inflammatory drug‐induced urticaria
Authors: Inmaculada Doña, Raquel Jurado‐Escobar, James R. Perkins, Pedro Ayuso, María Carmen Plaza‐Serón, Natalia Pérez‐Sánchez, Paloma Campo, Gador Bogas‐Herrera, Joan Bartra, María José Torres, Marek Sanak, José Antonio Cornejo‐García
Journal: Allergy (2019)

Abstract Background The role of arachidonic acid metabolites in NSAID ‐induced hypersensitivity has been studied in depth for NSAID ‐exacerbated respiratory disease ( NERD ) and NSAID ‐exacerbated cutaneous disease ( NECD ). However, no information is available for NSAID ‐induced urticarial/angioedema ( NIUA ), despite it being the most frequent clinical entity induced by NSAID hypersensitivity. We evaluated changes in leukotriene and prostaglandin metabolites for NIUA patients, using patients with NECD and single‐ NSAID ‐induced urticaria/angioedema or anaphylaxis ( SNIUAA ) for comparison. Methods Urine samples were taken from patients with confirmed NSAID ‐induced urticaria and healthy controls, at baseline and at various time intervals after ASA administration. Eicosanoid measurement was performed using high‐performance liquid chromatography‐tandem mass spectrometry and gas chromatography‐mass spectrometry. Results No differences were found between groups at baseline. Following ASA administration, LTE 4 and 9α,11β‐ PGF 2 levels were increased in both NIUA and NECD patients compared to baseline, rising initially, before decreasing toward initial levels. In addition, the levels of these metabolites were higher in NIUA and NECD when compared with the SNIUAA and control groups after ASA administration. No changes were found with respect to baseline values for SNIUAA and control groups. Conclusions We present for the first time data regarding the role of COX ‐1 inhibition in NIUA . Patients with this entity show a similar pattern eicosanoid levels following ASA challenge to those with NECD . Further studies will help ascertain the cell populations involved and the underlying molecular mechanisms.
Abstract 15937: Abnormal Left Ventricular Conduction is Associated With Increased Cardiovascular Mortality Compared to Abnormal Right Ventricular or Normal Conduction: Insights From the Precision Trial
Authors: Erich L Kiehl, Venu Menon, Kyle T Mandsager, Katherine E Wolski, Lisa Wisniewski, Steven E Nissen, A. M Lincoff, Jeffrey S Borer, Thomas F Luscher, Daniel J Cantillon
Journal: Circulation (2017)

Background: The prognosis associated with abnormal intra-ventricular conduction on surface ECG is unclear, particularly among patients without established cardiovascular (CV) disease. Methods: The ...
Abstract P189: Age-related Differences in Antihypertensive Medication Adherence in Hispanics: A Cross-sectional Community Based Survey in New York City
Authors: Priti Bandi, Emily Goldmann, Nina S Parikh, Parisa Farsi, Bernadette Boden-Albala
Journal: Circulation (2017)

Introduction: U.S. Hispanics, particularly younger adults in this population, experience a disproportionate burden of uncontrolled hypertension. Little is known about predictors of antihypertensive medication adherence - a major determinant of hypertension control and cardiovascular disease - and differences between age groups in this fast-growing population. Methods: The study included 1,043 community dwelling Hispanic hypertensives residing in three Northern Manhattan neighborhoods. Age-stratified analyses assessed the prevalence and predictors of high medication adherence (score 8 on Morisky Medication Adherence Scale, MMAS-8) among younger (&lt;60 years) and older (≥60 years) Hispanic adults. Results: Prevalence of high adherence was significantly lower in younger vs. older adults (24.5% [105 of 429] vs. 34.0% [209 of 614], p=0.001). In younger adults, heavy alcohol consumption, a longer duration of hypertension, and recent poor physical health were negatively associated with high adherence, but poor self-rated general health was positively associated with high adherence. In older adults, age, education level, knowledge of hypertension control, private insurance/Medicare vs. Medicaid and poor health-related activity limitations were negatively associated with high adherence. Conclusion: Equitable achievement of national hypertension control goals will require particular attention to suboptimal antihypertensive medication adherence found in this study and other samples of U.S. Hispanics, particularly in younger adults. Age differences in predictors of high adherence highlight the need to tailor efforts to the specific life stage of hypertensive individuals.
Landscape of TP53 Abnormalities and Their Clinical Relevance in Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia
Authors: Guillermo Montalban-Bravo, Christopher B. Benton, Rashmi Kanagal-Shamanna, Koji Sasaki, Rita Assi, Tapan M. Kadia, Farhad Ravandi, Irene Ganan-Gomez, Jorge E. Cortes, Naval G. Daver, Koichi Takahashi, Courtney D. DiNardo, Elias J. Jabbour, Gautam Borthakur, Naveen Pemmaraju, Marina Y. Konopleva, Sherry A. Pierce, Carlos E. Bueso-Ramos, Steven M. Kornblau, Keyur Patel, Simona Colla, Hagop M. Kantarjian, Michael Andreeff, Guillermo Garcia-Manero
Journal: Blood (2018)
Universal screening for Clostridioides difficile in a tertiary hospital: risk factors for carriage and clinical disease
Authors: E. Meltzer, G. Smollan, A. Huppert, R. Fluss, I. Tal, M. Gilboa, T. Zilberman-Daniels, N. Keller, G. Rahav, G. Regev-Yochay
Journal: Clinical Microbiology and Infection (2019)
Environmental Tobacco Smoke Affects Lung Function of Preschoolers with Asthma Even after a Decade
Authors: Katariina Lajunen, Satu Kalliola, Anne Kotaniemi-Syrjänen, L. Pekka Malmberg, Anna S. Pelkonen, Mika J. Mäkelä
Journal: American Journal of Respiratory and Critical Care Medicine (2018)
Phase II trial of preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by postoperative gemcitabine (GEM) in patients (pts) with borderline resectable pancreatic ductal adenocarcinomas (BR-PDAC).
Authors: Changhoon Yoo, Kyu-Pyo Kim, Ki Byung Song, Sang Soo Lee, Do Hyun Park, Tae Jun Song, Seung Soo Lee, Jin-hong Park, Dae Wook Hwang, Jae Hoon Lee, Sang Hyun Shin, Eunseon Shin, Baek-Yeol Ryoo, Song Cheol Kim
Journal: Journal of Clinical Oncology (2019)

342 Background: mFOLFIRINOX and GEM are standard chemotherapy for metastatic and resected PDAC, respectively. This phase 2 trial assessed the efficacy and safety of perioperative chemotherapy consisted of preoperative mFOLFIRINOX and postoperative GEM in pts with BR-PDAC. Methods: Pts with histologically proven and radiologically confirmed BR-PDAC as defined by NCCN criteria were eligible. Pts received 8 cycles of preoperative mFOLFIRINOX (oxaliplatin 85 mg/m 2 , irinotecan 180 mg/m 2 , 5-FU 2,400 mg/m 2 over 46 hours, and leucovorin 400 mg/m 2 ), every 2 weeks. For pts who underwent surgery, postoperative GEM (1,000 mg/m 2 D1, 8, 15, every 4 weeks) was given for 6 cycles. Primary endpoint was 1-year progression-free survival (PFS) rate and secondary endpoints were PFS, overall survival (OS) and curative surgery rate. A total of 44 pts were required to show the improvement in 1-year PFS rates from 30% to 50% with a two-sided alpha of 0.05, beta of 0.8 and drop-out rates of 10%. Results: Between May/2016 and Mar/2018, 44 patients were enrolled. Median age was 60 years (range, 35-76) and 26 pts (59%) were male. Pancreas head was most common site (n = 26, 59%). With mFOLFIRINOX, response rate was 34% and surgery was done in 27 patients (61%); 22 and 5 patients achieved R0 and R1 resection, respectively, and postoperative GEM was given in 24 patients (89%). With median follow-up of 16.6 months (95% CI, 10.9-22.2), 1-year PFS rate was 51.7% (95% CI, 35.2-68.2), and median PFS and OS was 13.0 months (95% CI, 7.7-18.4), and 14.3 months (95% CI, not available), respectively. PFS and OS were significantly differed according to the surgery (p &lt; 0.001 for both) and response to mFOLFIRINOX (p &lt; 0.001 and p = 0.03, respectively). Relative dose intensities of irinotecan, oxaliplatin and 5-FU were &gt; 77% during mFOLFIRINOX. Grade 3-4 neutropenia (55%), anemia (14%), nausea (11%), and diarrhea (7%) were most common severe toxicities and 3 pts (7%) discontinued mFOLFIRINOX due to the toxicities. Conclusions: Perioperative chemotherapy using mFOLFIRINOX and GEM were feasible and effective for pts with BR-PDAC. Future randomized trial is warranted. Clinical trial information: NCT02749136.
Lifetime Work Productivity Gains Among Patients with Chronic Rhinosinusitis with Nasal polyps (CRSwNP) Treated with EDS-FLU
Authors: Fulton F. Velez, Harry J. Sacks, John C. Messina, Victoria Dennison, Nathaniel Smith, Daniel C. Malone, Ramy A. Mahmoud
Journal: Journal of Allergy and Clinical Immunology (2019)
Efficacy and Safety of Dupilumab in Patients with Chronic Rhinosinusitis with Nasal Polyps: Results from the Randomized Phase 3 Sinus-24 Study
Authors: Joseph K. Han, Claus Bachert, Martin Desrosiers, Tanya M. Laidlaw, Claire Hopkins, Wytske J. Fokkens, Pierluigi Paggiaro, Seong Ho Cho, Heidi Olze, Leon S. Greos, Mei Zhang, Chunpeng Fan, Steven Draikiwicz, Nikhil Amin, Siddhesh Kamat, Asif Khan, Gianluca Pirozzi, Neil M.H. Graham, Marcella Ruddy, Heribert Staudinger, Leda P. Mannent
Journal: Journal of Allergy and Clinical Immunology (2019)
Abstract 16540: MicroRNA 145 Prevents Infarct Scar Expansion and May be a New Target for Cardiac Restoration After Myocardial Infarction
Authors: Hui-Fang Song, Sheng He, Shu-Hong Li, Zhengbo Shao, Jun Wu, Guo-qing Du, Jie Wu, Wenjuan Yin, Jiao Li, Richard D Weisel, Ren-Ke Li
Journal: Circulation (2016)

Introduction: Progressive heart failure following an MI results from adverse cardiac remodeling with infarct expansion and ventricular dilatation. The prevention of this process requires the identi...
Timing after neoadjuvant therapy predicts mortality in patients undergoing esophagectomy.
Authors: Taylor Maramara, Jamie Huston, Ravi Shridhar, Kenneth L Meredith
Journal: Journal of Clinical Oncology (2019)

157 Background: Neoadjuvant therapy (NT) prior to esophagectomy has dramatically improved survival in patients with esophageal cancer. Currently, most surgeons will allow 6-12 weeks after NT prior to recommending esophagectomy. Given that complete pathologic response (pCR) correlates to an improvement in survival, some have advocated a longer interval should be entertained to increase the pathologic response. The impact of an expanded NT-surgery timing is not currently well understood. Methods: Utilizing the National Cancer Database, we identified patients with esophageal cancer who underwent NT followed by esophagectomy. Patients were divided into 4 time intervals: &lt; 6 wks, 6-12 wks, 3-6 mo, and &gt; 6 mo. Mann-Whitney U, Kruskal Wallis, and Pearson’s Chi-square test were used as appropriate. Survival analyses were performed using the Kaplan-Meier method and p &lt; 0.05 was considered significant. Results: We identified 9,256 patients who received NT followed by esophagectomy. There were 8,053 (87%) adenocarcinomas and N = 1203 (13%) squamous cell carcinomas. 7,858 (84.9%) were male and 1,398 (15.1%) female with a median age was 62 (24-88). R0 resections decreased as the NT-Surgery interval increased: &lt; 6 wks, 6-12 wks, 2-6 mos, and &gt; 6 mos at 93%, 94.1%, 94.1%, and 86.2% respectfully p = 0.004. Additionally, the median lymph nodes harvested decreased as timing increased: 12, 12, 10, and 9 p &lt; 0.001 and the median nodes positive decreased as timing increased 1.5, 1.3, 1.1, and 2.4 p = 0.01. The complete response rates increased as timing increased 15.5%, 20.1%, 22.7%, and 25.8% p &lt; 0.001. However, this improvement in pCR did not translate into an increase in median survival: &lt; 6 wks 40.9 mos, 6-12 weeks 38.5 mos, 3-6 mos 34.8 mos, and &gt; 6 mos 39.8 mos of survival, p = 0.94 90-day mortality increased as the timing from neoadjuvant therapy increased: 6.4%, 7.9%, 9.4%, and 16.0%, respectively p = 0.001. Conclusions: Our data demonstrates that patients who have a prolonged NT- esophagectomy interval will have a substantial increase in 90-day mortality. While there was an increase in pathologic complete response rates, this did not translate into an improvement in survival. The current recommendations of a NT-surgery timing of 6-12 weeks should remain.
CD20 Expression and Response to Rituximab Treatment in B-Cell Precursor Lymphoblastic Leukemia - Results of the GMALL 08/2013 Trial
Authors: Monika Szczepanowski, Johanna Richter, Britta Kehden, Matthias Ritgen, Heiko Trautmann, Henrik Knecht, Mustafa Kondakci, Christoph Faul, Björn Steffen, Andreas Viardot, Michael Kneba, Dieter Hoelzer, Nicola Goekbuget, Monika Brüggemann
Journal: Blood (2018)
Preliminary Results from Accelerate, an International, Web-Based, Natural History Registry of Castleman Disease
Authors: David C Fajgenbaum, Sheila K Pierson, Dustin Shilling, Cooper Gardner, Amy Y Liu, Jasira Ziglar, Shawnee Bernstein, Sarah Mann, Jeremy Zuckerberg, Martin Lukac, Raj Kuhan Jayanthan, Mary Guilfoyle, Craig Tendler, Jason R Ruth, Thomas S Uldrick, Frits van Rhee
Journal: Blood (2017)
Abstract O.14: Incidence rate of recurrent Kawasaki disease in Japan (2003-2012)
Authors: Daisuke Sudo, Yosikazu Nakamura
Journal: Circulation (2015)

To investigate the incidence of recurrent Kawasaki disease, data of nationwide surveys of Kawasaki disease in Japan from January 2003 (18th survey) to December 2012 (22th survey) are analyzed. Our group previously reported the incidence rate of recurrent Kawasaki disease (Nakamura et al., 1994 and Hirata et al., 2001). In the current study, 104,751 patients with 498,388.9 person-years are observed to calculate the rate of recurrence. The incidence rate of recurrence is 4.14 per 1,000 person-years, with a high incidence within the 12 months from the first episode. The observed person-year categorized by some variables is calculated, such as sex, age at first episode, period of time after the initial episode, presence of cardiac sequelae in the acute (within 2 months) and late (after 2 months) stage, exposure to intravenous gamma globulin (IVGG) therapy, presence of additional IVGG administration, and exposure to steroid therapy. Using those data, incidence rate of recurrent Kawasaki disease and incidence rate ratio are calculated according to such variables, and potential risk factors for recurrence of Kawasaki disease are discussed.
Accumulation of JAK Activation-Loop Phosphorylation Promotes Type I JAK Inhibitor Withdrawal Syndrome in Myelofibrosis
Authors: Denis Tvorogov, Daniel Thomas, Nicholas P.D Liau, Mara Dottore, Emma F Barry, Maya Lathi, Winnie L Kan, Tim R Hercus, Frank Stomski, Timothy P. Hughes, Vinay Tergaonkar, Michael W Parker, David M Ross, Jeffrey J Babon, Ravindra Majeti, Angel F. Lopez
Journal: Blood (2018)
Reply
Authors: Kenji Okumura, Takahito Sone, Shuji Morikawa, Hideyuki Tsuboi, Hiroaki Mukawa, Itsuro Morishima, Michitaka Uesugi, Yasuhiro Morita, Yasushi Numaguchi, Toyoaki Murohara
Journal: Journal of the American College of Cardiology (2009)
Metabolomics assessment reveals oxidative stress and altered energy production in the heart after ischemic acute kidney injury in mice
Authors: Benjamin M. Fox, Hyo-Wook Gil, Lara Kirkbride-Romeo, Rushita A. Bagchi, Sara A. Wennersten, Korey R. Haefner, Nataliya I. Skrypnyk, Carolyn N. Brown, Danielle E. Soranno, Katja M. Gist, Benjamin R. Griffin, Anna Jovanovich, Julie A. Reisz, Matthew J. Wither, Angelo D'Alessandro, Charles L. Edelstein, Nathan Clendenen, Timothy A. McKinsey, Christopher Altmann, Sarah Faubel
Journal: Kidney International (2019)
In vitro degradation and biocompatibility evaluation of typical biodegradable metals (Mg/Zn/Fe) for the application of tracheobronchial stenosis
Authors: Yangyang Li, Jianglong Yan, Wenhao Zhou, Pan Xiong, Pei Wang, Wei Yuan, Yufeng Zheng, Yan Cheng
Journal: Bioactive Materials (2019)

Tracheobronchial obstruction in children due to benign stenosis or tracheobronchomalacia still remains a challenging matter of concern. Currently, there is 10%-20% complication rate in clinical treatment. The non-biodegradable property of silicone stents and nickel-titanium memory alloy stents take the primary responsibility for drawbacks including stimulating local granulation tissue proliferation, displacement, and stent-related infections. Permanent tracheobronchial stent will be a persistent foreign object for a long time, causing excessive secretion of tracheal mucosa, ulceration and even perforation, which is particularly unsuitable for young children with persistent tracheal growth. In this study, the degradation and biocompatibility performance of three typical biodegradable metals were investigated as potential tracheobronchial stent materials. The results exhibited that these materials showed different degradation behaviors in the simulating respiratory fluid environment compared with SBF. Except for pure iron group, high purity magnesium and zinc showed favorable cell adhesion and proliferation in three culture methodologies (direct culture, indirect culture and extraction culture). The proper corrosion rate and good biocompatibility indicated that high purity magnesium and zinc may be good candidates as tracheobronchial stent materials.